RT Journal Article
SR Electronic
T1 Serological responses and six-month trajectories to COVID-19 Comirnaty and Spikevax booster vaccine, September 2021 to January 2022, London, United Kingdom
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.17.22271126
DO 10.1101/2022.02.17.22271126
A1 Ireland, Georgina
A1 Whitaker, Heather
A1 Ladhani, Shamez N
A1 Baawuah, Frances
A1 Subbarao, Sathyvani
A1 Elgohari, Suzanne
A1 Smith, Alexandra
A1 O’Brien, Michelle
A1 Whillock, Corinne
A1 Martin, Oliver
A1 Moss, Paul
A1 Ramsay, Mary E
A1 Amirthalingam, Gayatri
A1 Brown, Kevin E
YR 2022
UL http://medrxiv.org/content/early/2022/02/17/2022.02.17.22271126.abstract
AB In contrast to the increasing levels of high avidity S antibody measured by the Roche assay in the first 6 months following natural infection, marked waning is seen post 2 or 3 doses of vaccine. Although the kinetics differ between those with vaccine-induced immunity compared to those infected prior to vaccination (hybrid immunity), waning rates appear to be similar following 2 or 3 doses of vaccine. These data should allow countries to optimise the timing of future doses of vaccine.Competing Interest StatementMER reports that the Immunisation and Vaccine Preventable Diseases Division (UKHSA) has provided vaccine manufacturers with post-marketing surveillance reports on pneumococcal and meningococcal infection, which the companies are required to submit to the UK licensing authority in compliance with their risk management strategy. A cost-recovery charge is made for these reports.Funding StatementThis surveillance was funded by PHE, now UK Health Security AgencyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The CONSENSUS study/audit was approved by the UK Health Security Agency R&D Research Ethics and Governance Group. No: NR0253I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesApplications for relevant anonymised data should be submitted to the UK Health Security Agency Office for Data Release.